Para compra levitra puede ser visto como un desafío. Aumenta Smomenta, y todos los que se poco a poco abrumado, como es lógico, cada vez más hombres están diagnosticados con disfunción eréctil.

Marmur.us

Jonathan D. Marmur, MD, FACC, FRCP
Director of Cardiac Catheterization and Interventional Cardiology jonathan@marmur.com
Cellular Phone
917-885-8854
CERTIFICATION
American Board Certification in Interventional Cardiology Nov, 2000 FACC- Fellow of the American College of Cardiology Feb, 1995 American Board Certification in Cardiology March, 1990 Certificate of Competence in Cardiology, Royal College of Physicians of Canada Nov, 1988 FRCP- Fellow of the Royal College of Physicians and Surgeons of Canada, Specialist in Internal Medicine June, 1987 Diplomat of the American Board of Internal Medicine Jan, 1987 Diplomat of the National Board of Medical Examiners (USA) July, 1983 Licentiate of the Medical Council of Canada June, 1982 MD: Laval University (Quebec City, Canada) May, 1982 APPOINTMENTS
March 2007- present: Editorial Board of the Journal of Invasive Cardiology September 2005-present: Professor of Medicine, State University of New York Health Science Center at Brooklyn, NY June 2005-present: Research Core Director for NIH-sponsored Brooklyn Center for April 2004-present: Director of Clinical Research, Center for Cardiovascular and Muscle Research (CCMR), State University of New York at Brooklyn, NY January 2003-present: Director of Interventional Cardiology Fellowship Program, State University of New York Health Science Center at Brooklyn, NY January 2003- present: Editorial Board of the Journal of Cardiovascular January 2003-Sept 2005: Associate Professor of Medicine, State University of New York Health Science Center at Brooklyn, NY July 2001-2005: Editorial Board of the Journal of the American College of Cardiology January 1994-Dec 2002: Assistant Professor of Medicine, Attending Interventional Cardiologist, Mt. Sinai School of Medicine, NY July 1992-Dec 1993: Instructor in Medicine, Mt. Sinai School of Medicine, NY July 1988-June 1992: Cardiology Research Fellow and Coronary Angioplasty Fellow, Mount Sinai Medical Center, NY July 1986-June 1988: Clinical Cardiology Fellow: St. Michael's Hospital and Mount Sinai Hospital, University of Toronto, Canada July 1983-June 1986: Internal Medicine Resident: Montreal General Hospital, McGill July 1982-June 1983: Intern: Queen Elizabeth Hospital, McGill University, Canada July 1997: Preceptor to recipient of the American College of Cardiology/Merck Adult Cardiology Research Fellowship Award for 1997-98 June 1995: NIH General Clinical Research Center Award (Principal Investigator for Cardiovascular Project) June 1994: NIH Clinical Investigator Development Award (KO8 HL03210-01) June 1992: Denber Research Award for Excellence in Cardiovascular Research March 1992: American College of Cardiology, New York State Chapter Young Oct. 1990: Mt. Sinai Hosp., NY, Annual Research Day Award June 1990: Medical Research Council of Canada Fellowship Award July 1988: Canadian Heart and Stroke Foundation Research Fellowship Award May 1987: Ursula Bangs Research Competition Award, University of Toronto PUBLICATIONS
ORIGINAL ARTICLES
Poludasu S, Cavusoglu E, Clark LT, Marmur JD. Impact of gender on in-hospital percutaneous coronary interventional outcomes in African-Americans. J Invasive Cardiol. 2007;19:123-128. Babinska A, Azari BM, Salifu MO, Liu R, Jiang XC, Sobocka MB, Boo D, Al Khoury G, Deitch JS, Marmur JD, Ehrlich YH, Kornecki E. The F11 receptor (F11R/JAM-A) in atherothrombosis: Overexpression of F11R in atherosclerotic plaques. Thromb Haemost 2007;97:272–281. Cavusoglu E, Eng C, Chopra V, Clark LT, Pinsky DJ, Marmur JD. Low Plasma RANTES Levels Are an Independent Predictor of Cardiac Mortality in Patients Referred for Coronary Angiography. Arterioscler Thromb Vasc Biol. 2007 (in press). Sobocki T, Jayman F, Sobocka MB, Marmur JD, Banerjee P. Isolation, sequencing, and functional analysis of the TATA-less murine ATPase II promoter and structural analysis of the ATPase II gene. Biochimica et Biophysica Acta 2007;1769:61–75. Marmur JD, Poludasu S, Agarwal A, Vladutiu P, Feit A, Lapin R, Cavusoglu E. Bolus- only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol. 2006;18:521-526. Marmur JD, Mitre CA, Barnathan E, Cavusoglu E. Benefit of Bolus-Only Platelet Glycoprotein IIb/IIIa Inhibition During Percutaneous Coronary Intervention: Insights From the Very Early Outcomes in the EPIC Trial. Am Heart J. 2006; 2006;152:876- Cavusoglu E, Chopra V, Gupta A, Ruwende C, Yanamadala S, Eng C, Clark LT, Pinsky DJ, Marmur JD. Usefulness of the white blood cell count as a predictor of angiographic findings in an unselected population referred for coronary angiography. Cavusoglu E, Chopra V, Gupta A, Clark LT, Eng C, Marmur JD. Usefulness of anemia in men as an independent predictor of two-year cardiovascular outcome in patients presenting with acute coronary syndrome. Am J Cardiol 2006;98:580-584. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, Pinsky DJ, Marmur JD. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J. 2006;27:2300-2309. Akerman MJ, Yaegashi M, Khiangte Z, Murugan AT, Abe O, Marmur JD. Bronchodilator effect of infused B-type natriuretic peptide in asthma. Chest Kokolis S, Marmur JD, Clark LT, Kassotis J, Kokolis R, Cavusoglu E, Lapin R, Breitbart S, Lazar JM. Effects of alcoholism on coronary artery disease and left ventricular dysfunction in male veterans. J Invasive Cardiol. 2006;18:304-307. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, Pinsky DJ, Marmur JD. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J. 2006 May;151(5):1108.e1-8. Cavusoglu E, Lakhani M, Marmur JD. The Activated Clotting Time (ACT) Can Be Used to Monitor Enoxaparin and Dalteparin after Intravenous Administration. J Invasive Cardiol 2005;17:416-421. Richardson MW, Hostalek L, Michellebson M, Hu J, Shippy R, Siwkowski A, Marmur JD, Khalili K, Klotman PE, Hampel A, Rappaport J. Design, Targeting, and Initial Screening of sTRSV- Derived Hairpin Ribozymes for Optimum Helix 1 Length and Catalytic Efficiency In Vitro. Methods Mol Biol 2004;252:339-358. Kini AS, Lee P, Marmur JD, Agarwal A, Duffy ME, Kim MC, Sharma SK. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol 2004;93:18-23. Sharma SK, Kini A, Mehran R, Lansky A, Kobayashi Y, Marmur JD. Randomized trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-stent Restenosis Kini AS, Lee PC, Mitre CA, Kim MC, Kamran M, Duffy ME, Marmur JD, Sharma SK. Prediction of outcome after percutaneous coronary intervention for the acute coronary syndrome. Am J Med 2003;115:708-714. Doshi SN, Kini A, Kim MC, Payne N, Kamran M, Sherman W, Marmur JD, Sharma SK. A comparative study of rotational atherectomy in acute and stable coronary syndromes in the modern era. Am J Cardiol 2003;92:1404-1408. Marmur JD, Anand SX, Bagga RS, Fareed J, Pan C-M, Sharma SK, Richard MF. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003;41:394-402. Kini AS, Richard M, Suleman J, Perez N, Lee P, Fisher EA, Kamran M, Marmur JD, Sharma SK. Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). Am J Cardiol 2002;90:526-529. Lev EI, Marmur JD, Zdravkovic M, Osende JI, Robbins J, Delfin JA, Richard M, Erhardtsen E, Thomsen MS, Lincoff AM, Badimon JJ. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa; an ex-vivo human study. Arterioscler Cavusoglu E, Chen I, Rappaport J, Marmur JD. Inhibition of tissue factor gene induction and activity using a hairpin ribozyme. Circulation 2002;105:2282-2287. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-1297. Kini AS, Mitre CA, Kamran M, Suleman J, Kim M, Duffy ME, Marmur JD, Sharma SK. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol Osende JI, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD, Richard M, Varon D, Badimon JJ. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests. Relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 2001;103:1488-1491. Lev EI, Osende JI, Richard MF, Robbins JA, Delfin JA, Rodriguez O, Sharma SK, Jayasundera T, Badimon JJ, Marmur JD. Administration of abciximab to patients receiving tirofiban or eptifibatide – effect on platelet function. J Am Coll Cardiol Kini A, Reich D, Marmur JD, Mitre CA, Sharma SK. Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: Results of the Rota ReoPro randomized trial. Am Heart J 2001;142:965-969. Tan RP, Kini A, Shalouh E, Marmur JD, Sharma SK. Optimal treatment of nonaorto ostial coronary lesions in large vessels: acute and long-term results. Cathet Sharma SK, Kini A, Marmur JD, Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival. Circulation 2000;102:166-172. Hayes R, Chesebro JH, Fuster V, Dangas G, Fallon JT, Sharma SK, Coller BS, Badimon L, Marmur JD, Badimon JJ. Antithrombotic effects of abciximab. Am J Cardiol 2000;85:1167-1172. Dangas G, Ambrose JA, Rehmann D, Marmur JD, Sharma SK, Hemdal-Monsen C, Sanborn TA, Fischman DL. Balloon optimization versus stent study (BOSS): provisional stenting and early recoil after balloon angioplasty. Am J Cardiol. Kini A, Marmur JD, Dangas G, Choudhary S, Sharma SK. Angiographic patterns of in-stent restenosis and implications on subsequent revascularization. Catheter Kini A, Kini S, Marmur JD, Bertea T, Dangas G, Cocke TP, Sharma SK. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. Catheter Cardiovasc Interv 1999;48:123-129. Kini A, Marmur JD, Kini S, Dangas G, Cocke TP, Wallenstein S, Brown E, Ambrose JA, Sharma SK. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course: implications for early discharge after coronary intervention. J Am Coll Cardiol Dangas G, Ambrose JA, Sharma SK, Shao JH, Feldman D, Cohen AM, Marmur JD, Cocke TP, Duvvuri S, Goldman ME. The effect of early postinfarction revascularization of asymptomatic patients on left ventricular remodeling. Coron Artery Dis 1999;10:203-210. Dangas G, Marmur JD, King TE, De Leon J, Sharma SK, Vidhun R, Feldman D, Stoynov MY, Badimon JJ, Ambrose JA. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. Am Heart J 1999;138:49-54. Kini A, Marmur JD, Duvvuri S, Dangas G, Choudhary S, Sharma SK. Rotational atherectomy: improved procedural outcome with evolution of technique and equipment. Single-center results of first 1,000 patients. Catheter Cardiovasc Interv 1999;46:305-311. Williams MS, Coller BS, Vaananen HJ, Scudder LE, Sharma SK, Marmur JD. Activation of platelets in platelet-rich plasma by rotablation is speed dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro). Circulation 1998;98:742-748. Dangas G, Badimon JJ, Coller BS, Fallon JT, Sharma SK, Hayes RM, Meraj P, Ambrose JA, Marmur JD. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition. Implications for a potential anticoagulant effect of abciximab. Arterioscler Thromb Vasc Biol 1998;18:1342-1349. Dangas G, Peters-Veluthamaningal C, Cocke TP, Vidhun R, Duvvuri S, Marmur JD, Sharma SK. Histopathological correlates of early arterial recoil following directional coronary atherectomy. Cardiology 1998;90:32-36 Sharma SK, Duvvuri S, Dangas G, Kini A, Vidhun R, Venu K, Ambrose JA, Marmur JD. Rotational atherectomy for in-stent restenosis: acute and long-term results of the first 100 cases. J Am Coll Cardiol 1998;32:1358-65. Taub PJ, Marmur JD, Zhang WX, Senderoff D, Nhat PD, Phelps R, Urken ML, Silver L, Weinberg H. Locally administered vascular endothelial growth factor cDNA increases survival of ischemic experimental skin flaps. Plast Reconstr Surg 1998;102:2033-2039. Taub PJ, Marmur JD, Zhang WX, Senderoff D, Urken ML, Silver L, Weinberg H. Effect of time on the viability of ischemic skin flaps treated with vascular endothelial growth factor (VEGF) cDNA. J Reconstr Microsurg 1998;14:387-390. Dangas G, Cocke TP, Sharma SK, Vidhun RR, Kakarala V, Marmur JD, Ambrose JA. Early Changes in Minimal Luminal Diameter After Balloon Angioplasty and Directional Coronary Atherectomy. J Invasive Cardiol. 1998;7:372-375. Sharma SK, Dangas G, Mehran R, Duvvuri S, Kini A, Cocke TP, Kakarala V, Cohen AM, Marmur JD, Ambrose JA. Risk factors for the development of slow flow during rotational coronary atherectomy. Am J Cardiol 1997;80:219-222. Marmur JD, Sharma SK, Weinrauch M, Kantrowitz N, Dangas G, Kokinakkis S, Ambrose JA. Thrombin generation and activity during coronary angioplasty: influence of angiographic lesion morphology. J Inv Cardiol 1997;9:410-416. Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB. The identification of active tissue factor in human coronary atheroma. Circulation 1996;94:1226-1238. Marmur JD, Merlini PA, Sharma SK, Khaghan N, Israel DH, Torre SR, Ardissino D, Ambrose JA. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 1994;24:1484-1491. Ambrose JA, Almeida OD, Sharma SK, Torre SR, Marmur JD, Israel DH, Ratner DE, Weiss MB, Monsen CE, Myler RK, Moses J, Unterecker WJ, Grunwald AM, Garrett JS, Cowley MJ, Anwar A, Sobolski J. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA trial. Circulation 1994;90:69-77. Alexopoulos D, Sanborn TA, Marmur JD, Badimon JJ, Badimon L, Dische R, Fuster V. Acute biological response to laser balloon angioplasty in the atherosclerotic rabbit. Lasers Surg Med 1994;14:7-12. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993;91:2253-9. Taubman MB , Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson Y. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells: Role of Ca2+ mobilization and protein kinase C activation. J Clin Invest Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, Nadal-Ginard B. JE mRNA accumulates rapidly in aortic injury and in PDGF-stimulated vascular smooth Marmur JD, Sanborn T, Kahn H, Badimon L, Fuster V. The acute biological response to excimer versus thermal laser angioplasty in experimental atherosclerosis. J Am Marmur JD, Freeman MR, Langer A, Armstrong PW. Prognosis in medically stabilized unstable angina: early Holter ST segment monitoring vs predischarge exercise tomography. Annals of Internal Medicine 1990; 113:575-579. Sanborn TA, Alexopoulos DA, Marmur JD, Kahn H, Badimon JJ, Badimon L, Fuster V. Coronary excimer laser angioplasty: reduced complications and Indium-111 platelet accumulation compared to laser thermal angioplasty. J Am Coll Card 1990;16:502-506. CASE REPORTS
M Kokolis S, Feit A, Marmur JD. Coronary air embolization in the left coronary artery. Mungee S, Lapin R, Cavusoglu E, Clark LT, Marmur JD. Percutaneous coronary intervention in a patient with congenital Factor XI deficiency and acquired inhibitor. Catheter-induced spasm of the left main coronary artery due to anatomic "kinking" in its course.Lingegowda US, Marmur JD, Cavusoglu E. J Invasive Cardiol. Doshi SN, Marmur JD. Resolution of intracoronary thrombus with direct thrombin inhibition in a cocaine abuser. Heart. 2004;90:501. Doshi SN, Marmur JD, Kamran M. Successful use of the Guardwire Plus distal embolisation protection device in a native left anterior descending coronary artery. Heart. 2002;88:648. Jayasundera TG, Feldman DN, Marmur JD. Tirofiban-induced coronary thrombolysis. J Invasive Cardiol 1999;3:138-140. REVIEW ARTICLES
Marmur JD, Bullock-Palmer RP, Lakhani MJ, Cavusoglu E. Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention. J Invasive Cardiol 2006;18 Suppl E:1E-13E. Bullock-Palmer RP, Lakhani MJ, Marmur JD. Lessons learned from the use of low- molecular-weight heparin in the cardiac catheterization laboratory- a series of case reports. J Invasive Cardiol 2006;18 Suppl E:14E-18E. Kokolis S, Clark LT, Cavusoglu E, Marmur JD. Direct thrombin inhibitor use during percutaneous coronary intervention. J Cardiovasc Pharmacol. 2005;45:270-279. Kokolis S, Cavusoglu E, Clark LT, Marmur JD. Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low- molecular-weight heparins, and direct thrombin inhibitors. Prog Cardiovasc Dis. 2004;46:506-23. Cavusoglu E, Chhabra S, Marmur JD, Kini A, Sharma SK. The prevention of contrast- induced nephropathy in patients undergoing percutaneous coronary intervention. Minerva Cardioangiol. 2004;52:419-32. Cavusoglu E, Kini AS, Marmur JD, Sharma SK. Current status of rotational atherectomy. Catheter Cardiovasc Interv. 2004;62:485-98. Chopra V, Marmur JD, Cavusoglu E. The role of clopidogrel in the management of patients with ischemic heart disease. Cardiovasc Drugs Ther. 2003;17:467-77. Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003;90:377-84. Cavusoglu E, Cheng J, Bhatt R, Kunamneni PB, Marmur JD, Eng C. Clopidogrel in the management of ischemic heart disease. Heart Dis 2003;5:144-52. Marmur JD. Direct versus indirect thrombin inhibition in percutaneous coronary intervention. J Invasive Cardiol 2002;14 Suppl B:8B-18B. Doshi SN and Marmur JD. Evolving role of tissue factor and its inhibitor. Crit Care Med 2002;30 (5 Suppl):S241-S250. Marmur JD and Cavusoglu E. The use of the glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary intervention. J Interven Cardiol 2002;15:71-84. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, Marmur JD, Nemerson Y. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 1997;78:200-204. Marmur JD, Taubman MB, Fuster V. The pathophysiology of restenosis: the role of platelets and thrombin. J Vasc Med Biol 1993;4:55-63. Marmur JD, Poon M, Rossikhina M, Taubman MB. Induction of PDGF-responsive genes in vascular smooth muscle. Implications for the early response to vessel injury. Circulation 1992;86(Suppl III):III-53-III-60. BOOK CHAPTERS
Fier CM and Marmur JD. Gene Therapy to Stabilize Atherosclerotic Plaque. In Brown DL, ed. Cardiovascular Plaque Rupture. Marcel Dekker, Inc., New York, NY, 2002; Marmur JD. Gene Therapy and the Vessel Wall. In Marks A and Taubman MB, ed. Molecular Biology of Cardiovascular Disease. Marcel Dekker, Inc., New York, NY, 1997; 379-400. Marmur JD and Venditto J. Biochemical Markers and Complex Lesion Morphology. In Ambrose JA, ed. Complex Coronary Lesions in Acute Coronary Syndromes. Futura Publishing Co., Armonk, NY, 1995; 117-139. Taubman MB, Poon M, Marmur JD, Wax SD. Gene induction in vessel wall injury: implications for restenosis after angioplasty. In: Woodford FP, Davignon J, Sniderman A, ed. Atherosclerosis X. Amsterdam: Elsevier Science B. V., 1995; 1024-1027. INVITED LECTURES
June 2005: The Evolving Role of Anticoagulation in Coronary Intervention. 3rd Annual New Jersey Cardiovascular Symposium: An Update in the Management of Acute Coronary Syndromes and Heart Failure. Newark, NJ. March 2005: Unfractionated Heparin Is Obsolete in the Cath Lab-Opening Arguments/Rebuttal, Protagonist. Debate at the ACC Annual Scientific Sessions, September 2004: Monitoring of Low Molecular Weight Heparins - from Theory to Practice. Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific April 2004: Enoxaparin in Acute Coronary Syndromes and Percutaneous Coronary Intervention. Interventional Cardiology Review Course, San Jose, CA. September 2003: The Emerging Role of Natriuretic Peptides in Percutaneous Coronary Intervention. Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Sessions, Washington, DC. July 2003: Anticoagulant effects of LMWHs in surgical and interventional indications. Presented to the WHO Working Group on Unfractionated Heparin and Low Molecular Weight Heparin / Working Party on Monitoring of Low Molecular Weight Heparin. Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, 49th Annual Meeting, Birmingham, UK June 2003: Intravenous Low Molecular Weight Heparin During PCI. Tenth International Symposium on Thromboembolism, London, England. March 2003: Role and Controversies of Antithrombin Therapy in the Cardiac Catheterization Laboratory. 4th Annual Antithrombotic Therapy Symposium, Detroit, January 2003: Adjunct Pharmacology for PCI. Cardiovascular Revascularization Therapy 2003, Washington, DC. Oct. 2002: Anti-inflammatory Effects of Anti-platelet Agents. Sixth Annual Scientific Meeting of the Insitute of Cardiovascular Science and Medicine, Hong Kong. September 2002: Low Molecular Weight Heparins and Direct Thrombin Inhibitors. Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Sessions, June 2002: Monitoring Antithrombotic Therapy During Arterial Intervention. Ninth International Symposium on Thromboembolism, Seville, Spain. September 2001: GPIIb/IIIa Inhibitors- New Trial Insights and Controversies. Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Sessions, July 2001: Direct Thrombin Inhibition in Percutaneous Coronary Intervention. Second International Congress on Heart Disease, Washington, DC. June 2001: Monitoring Low Molecular Weight Heparins During Coronary Intervention. Eighth International Symposium on Thromboembolism, Florence, Italy. May 2001: Challenges in the Modern Management of Complex Coronary and Peripheral Vascular Disease. Scripps Memorial Hospital, La Jolla, CA. March 2001: State of the Art Antithrombotic Therapy 2001. LMWH in Interventional Cardiology. Wayne State University, Dearborn, MI. March 2001: Adenoviral-mediated Angiogenic Gene Therapy. Annual Scientific Sessions of the American College of Cardiology, Orlando, FL. Nov. 2000: Low Molecular Weight Heparins in Coronary Intervention. Annual Scientific Sessions of the American Heart Association, New Orleans, LA. Oct. 2000: Oral Antiplatelet Agents. Interventional Cardiology Review Course, Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium , Washington, DC. August 2000: Congress of the European Society of Cardiology. Differentiation of Glycoprotein IIb/IIIa Inhibitors. Amsterdam, The Netherlands. May 2000: Paris Course on Revascularization. Switching Patients from Small Molecules to Abciximab. Paris, France. March 2000: Alternative Revascularization Strategies: PMR/DMR and Angiogenesis. Evening session panelist at the American College of Cardiology 49th Annual Scientific Sessions, Anahiem, CA. Oct. 1999: Tirofiban in the Management of Acute Coronary Syndromes. Symposium on Platelet GP IIb/IIIa Inhibitors. Lisbon, Portugal. Oct. 1999: Congress of the Korean Society of Circulation. Platelets as the target in thrombus formation. Seoul, Korea. Sept. 1999: Aspirin and Thienopyridines. Interventional Cardiology Review Course, Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium , Washington, DC. Sept. 1999: Keynote Address: New Pharmacologic Adjuncts in Coronary Intervention. Cardiac Intervention in Chicagoland, Chicago, Illinois. Sept. 1999: ACS Debate Club. Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Sessions, Washington, DC. Sept. 1999: Platelet Receptor Inhibitors. Cardiology Grand Rounds, University of Virginia, Charlottesville, VA. August 1999: Acute Myocardial Infarction: Invasive versus Medical Therapy. Invitational Cardiology Symposium, Akron General Medical Center, Akron, OH. June 1999: Gene Therapy for Therapeutic Angiogenesis. A Live Symposium of April 1999: Platelet Glycoprotein IIb/IIIa Receptor Blockers in Coronary Interventions: What Did We Learn from EPIC, EPILOG, EPISTENT, RESTORE, and March 1999: GPIIb/IIIa Inhibition in Acute Coronary Syndromes Management. CME Symposium at the 1999 Annual Meeting of the American College of Cardiology. New Jan. 1999: Indications for GP IIb/IIIa Inhibitors in Acute Coronary Syndromes and Percutaneous Coronary Interventions. St. Louis University Hospital, St. Louis, MO. Nov. 1998: New Paradigm in the Treatment of Acute Coronary Syndromes. The Role of Troponin and IIb/IIIa Inhibitor Therapy. Stony Brook University Hospital, NY. Sept. 1998: Interventional Cardiology Update 98. CK versus Troponin in the Diagnosis of Acute Coronary Syndromes and Periprocedural CK Elevation. Orlando, Sept. 1998: The Bernard and Helen Perlman Lecture: Platelet GP IIb/IIIa Receptor Blockers. The New York Cardiological Society, Inc. 70th Anniversary Program on Emerging Issues in the Practice of Cardiology. New York, NY. July 1998: Acute Coronary Syndromes: Incorporating New Therapies to an Established Algorithm of Care. Hartford, CT June 1998: Gene Therapy for the Management of In-stent Restenosis. A Live Symposium of Complex Coronary Cases. New York, NY. June 1998: Molecular Biology of Restenosis. Current Medical and Interventional Therapy in Acute Coronary Syndromes. New York, NY. April 1990: The Acute Biological Response to Excimer Versus Thermal Laser Angioplasty in Experimental Atherosclerosis. Symposium on Laser Angioplasty. University Hospital Utrecht, Maastricht, The Netherlands. MEDIA RESOURCE EDUCATIONAL MATERIALS
CD-ROM: Low Molecular Weight Heparin in the Cardiac Catheterization Laboratory. September 2002. (produced by alphaMED, New York, NY, and the Annenberg Center for Health Sciences at Eisenhower, 39000 Bob Hope Drive, Rancho Mirage, CA 92270). CD-ROM: The Evolving Role of Tissue Factor and its Inhibitor, TFPI. The Margaux Conference on Critical Illness, Sedona, AZ 2001 (produced by Remedica Communications, UK; www.remedica.com). CD-ROM: Antithrombotic drugs in Interventional Cardiology. 8th International Symposium on Thromboembolism. Palazao dei Congressi, Florence, Italy 2001 (produced by Remedica Communications, UK; www.remedica.com). CD-ROM: ACC Spotlight Series: ACCIS 2001. Alternative Revascularization Strategies. Orlando, FL 2001 (produced by PhysicianEd, Boston, MA). CD-ROM: Oral antiplatelet therapy. 3rd Annual Interventional Cardiology Self- Assessment Course. Washington, DC 2000 (produced by The Cardiovascular Research Foundation). CD-ROM: GP IIb/IIIa Inhibition in Acute Coronary Syndromes- Science and Practice. New Orleans, LA 1999 (produced by Conceptis Technologies, Montreal, Canada). Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) is an Independent Predictor of All-Cause Mortality, Cardiac Mortality, and Myocardial Infarction. Submitted December 2, 2004 by The Research Foundation of the State University of New York (SUNY). For more information, visit: www.RFSUNY.org.

Source: http://www.marmur.us/PDFs/cvdoc.pdf

Schweinegrippe: hysterie au.

Schweinegrippe: Hysterie auf Kosten von Tieren und Menschenhttp://www.aerzte-gegen-tierversuche.de/projekte/stellungnahme/330-. Schweinegrippe: Hysterie auf Kosten von Tieren und MenschenKaum ist die Vogelgrippe-Panikwelle ein wenig abgeebbt, rollt schon die nächste Flut an Hysterie an und einefilmreife Marketingkampagne für Pharmaprodukte wird in Szene gesetzt. Diesmal sind nicht Vögel a

Microsoft word - sondagepacterecherche.doc

Sondage sur le Pacte pour la Recherche Réalisé entre le 2 et le 9 décembre 2005 auprès de 500 PME innovantes technologiques 164 réponses traitées Résultats 84 % des PME jugent important que l’Etat mette en place des dispositifs favorisant l’accès des PME aux laboratoires publics . 83 % des PME sont favorables à la procédure CIFRE (convention industrielle de formation

Copyright © 2010-2014 PDF pharmacy articles